P1101 and Anti-PD1 for After Curative Surgery of Hepatitis B-related Hepatocellular Carcinoma
Status:
Recruiting
Trial end date:
2023-07-31
Target enrollment:
Participant gender:
Summary
The main purpose of this trial is to evaluate the safety of the new adjuvant treatment of
curative HCC, or the treatment of long-acting interferon P1101 alone, or the use of
long-acting interferon P1101 and subsequent treatment of anti-PD1, and any efficacy in
reducing the recurrence rate of patients after surgery.